FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Core Viewpoint - Savara Inc. is facing a federal securities class action due to allegations of misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI, which has led to significant investor losses [3][4]. Group 1: Allegations Against Savara - The complaint claims that Savara and its executives violated federal securities laws by making false or misleading statements about the MOLBREEVI BLA, including insufficient information regarding its chemistry and manufacturing [3]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [3]. - The public statements made by Savara were deemed materially false and misleading throughout the relevant period [3]. Group 2: Stock Price Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Legal Proceedings - Investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal rights and options [1][5]. - The deadline for seeking the role of lead plaintiff in the class action is November 7, 2025 [1].